These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19151774)

  • 21. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
    Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
    Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
    Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.
    Park BG; Chi HS; Park SJ; Min SK; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
    Acta Haematol; 2012; 127(2):63-71. PubMed ID: 22104247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features.
    Andersen MT; Andersen MK; Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2008 May; 22(5):951-5. PubMed ID: 18273044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.
    Schoch C; Haase D; Haferlach T; Gudat H; Büchner T; Freund M; Link H; Lengfelder E; Wandt H; Sauerland MC; Löffler H; Fonatsch C
    Leukemia; 1996 Aug; 10(8):1288-95. PubMed ID: 8709633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
    Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
    Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
    Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.
    Nahi H; Lehmann S; Bengtzen S; Jansson M; Möllgård L; Paul C; Merup M
    Leuk Lymphoma; 2008 Mar; 49(3):508-16. PubMed ID: 18297528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ.
    Soenen V; Preudhomme C; Roumier C; Daudignon A; Laï JL; Fenaux P
    Blood; 1998 Feb; 91(3):1008-15. PubMed ID: 9446663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial.
    Stölzel F; Pfirrmann M; Aulitzky WE; Kaufmann M; Bodenstein H; Bornhäuser M; Röllig C; Kramer M; Mohr B; Oelschlägel U; Schmitz N; Soucek S; Thiede C; Ehninger G; Schaich M;
    Leukemia; 2011 Mar; 25(3):420-8. PubMed ID: 21135859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.
    Ånensen N; Hjelle SM; Van Belle W; Haaland I; Silden E; Bourdon JC; Hovland R; Taskén K; Knappskog S; Lønning PE; Bruserud Ø; Gjertsen BT
    Oncogene; 2012 Mar; 31(12):1533-45. PubMed ID: 21860418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality.
    Sankar M; Tanaka K; Kumaravel TS; Arif M; Shintani T; Yagi S; Kyo T; Dohy H; Kamada N
    Leukemia; 1998 Apr; 12(4):510-6. PubMed ID: 9557609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
    Halldórsdóttir AM; Lundin A; Murray F; Mansouri L; Knuutila S; Sundström C; Laurell A; Ehrencrona H; Sander B; Rosenquist R
    Leukemia; 2011 Dec; 25(12):1904-8. PubMed ID: 21720382
    [No Abstract]   [Full Text] [Related]  

  • 38. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
    Krönke J; Bullinger L; Teleanu V; Tschürtz F; Gaidzik VI; Kühn MW; Rücker FG; Holzmann K; Paschka P; Kapp-Schwörer S; Späth D; Kindler T; Schittenhelm M; Krauter J; Ganser A; Göhring G; Schlegelberger B; Schlenk RF; Döhner H; Döhner K
    Blood; 2013 Jul; 122(1):100-8. PubMed ID: 23704090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance.
    Nakai H; Misawa S
    Leuk Lymphoma; 1995 Oct; 19(3-4):213-21. PubMed ID: 8535212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.
    Bochtler T; Granzow M; Stölzel F; Kunz C; Mohr B; Kartal-Kaess M; Hinderhofer K; Heilig CE; Kramer M; Thiede C; Endris V; Kirchner M; Stenzinger A; Benner A; Bornhäuser M; Ehninger G; Ho AD; Jauch A; Krämer A;
    Blood; 2017 Mar; 129(10):1333-1342. PubMed ID: 28119329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.